

ANTONELLA TRAMUTOLA

*Curriculum Vitae per la destinazioni “ai fini della pubblicazione in
ottemperanza del D.Lgs. 33/2013*

Place: Rome

Date: 28-09-2021

Part I – General Information

Full Name	Antonella Tramutola
Spoken Languages	Italian (mother tongue), English
Current Position	RTD-A SSD BIO/10 Department of Biochemical Sciences “A. Rossi-Fanelli” Sapienza University of Rome
ORCID	0000-0002-9564-2086
Scopus Author ID	53980710100



Part II – Education

Type	Year	Institution	Notes (Degree, Experience)
Licensure 01	2021	Italian Ministry of Education, University and Research (MIUR)	National Scientific Qualification as Associate Professor of Biochemistry (SSD BIO/11)
Licensure 02	2018	Italian Ministry of Education, University and Research (MIUR)	National Scientific Qualification as Associate Professor of Biochemistry (SSD BIO/10)
Second Level Specializing Master	11/2013	Institute of Pharmacology, Catholic University School of Medicine, Rome	Preclinical and Clinical Development of Drug
PhD	04/2013	Institute of Pharmacology, Catholic University School of Medicine Rome	Ph.D. in Neuroscience
Licensure 03	10/2010	<i>“Facoltà di Scienze MM.FF.NN.”</i> (Faculty of Science), University of Perugia	National Qualification as Biologist
University Graduation	10/2009	<i>“Facoltà di Scienze MM.FF.NN.”</i> (Faculty of Science), Sapienza University of Rome	Master’s degree in Neurobiology (summa cum laude)
University Graduation	10/2007	<i>“Facoltà di Scienze MM.FF.NN.”</i> (Faculty of Science), University of Perugia	Bachelor’s degree in Biological Science

Part III – Appointments

III.A – Academic Appointments

Start	End	Institution	Position
2020	present	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Faculty member for the PhD School in Biochemistry
10/2019	present	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Assistant Professor of Biochemistry, RTD-A (SSD BIO/10)

01/2016	09/2019	Department of Biochemical Sciences "A. Rossi-Fanelli", Sapienza University of Rome	Post-doctoral Researcher from Umberto Veronesi Foundation
01/2018	12/2018	Department of Biochemical Sciences "A. Rossi-Fanelli", Sapienza University of Rome	Post-doctoral Researcher from Umberto Veronesi Foundation
06/2013	12/2017	Department of Biochemical Sciences "A. Rossi-Fanelli", Sapienza University of Rome	Post-doctoral Researcher
03/2014	01/2015	(a) Department of Molecular and Biomedical Pharmacology and (b) Department of Chemistry, Laboratory of Neurochemistry University of Kentucky, Lexington, (KY), USA	Visiting Post-Doc
08/2006	02/2007	Neuroscience Centre of University of Helsinki, Helsinki, Finland	Visiting Student (ERASMUS Project)

III.B – Other Appointments

Start	End	Institution	Position
12/2007	10/2009	Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy	Visiting Scholar
09/2006	11/2006	Department of Biological Sciences, University of Helsinki, Helsinki, Finland	Visiting Student, ERASMUS Project
04/2005	07/2005	Department of Biological Sciences, University of Perugia	Visiting Student

III.C – Tutoring activities

Start	End	Institution	Position
2020	present	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Tutor , Simona Lanzillotta, Ph.D. in Biochemistry (XXXVI cycle), Sapienza University of Rome.
2019	present	Sapienza School for Advanced Studies (SSAS)	Tutor for a project presented and performed by Pietro Bertoldo (2019).
2019	present	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Supervisor of students from Higher Education Institutions within the Project “Alternanza Scuola-Lavoro”.
2018	present	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Tutor , Simona Lanzillotta, Ph.D. in Biochemistry (XXXIV cycle), Sapienza University of Rome.
2016	2018	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Tutor , Andrea Castellani, undergraduate student enrolled at the Pharmaceutical Chemistry and Technology degree, Faculty of Pharmacy and Medicine, Sapienza University of Rome.
2015	2018	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Tutor , Nidhi Sharma, Ph.D. in Biochemistry (XXXI cycle), Sapienza University of Rome.
2014	2017	Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome	Tutor , Andrea Arena, Ph.D. in Biochemistry (XXIX cycle), Sapienza University of Rome.
2011	2012	Institute of Pharmacology, Catholic University School of Medicine, Rome	Tutor , Sara Cerrini, undergraduate student, Pharmaceutical Chemistry and Technology degree, Faculty of Pharmacy and Medicine, Sapienza University of Rome.

External tutoring

2014	2015	Department of Chemistry, Laboratory of Neurochemistry University of Kentucky, Lexington, (KY), USA	Tutor , Xiaojia Ren, Ph.D. in Chemistry
------	------	--	--

Part IV – Teaching experience

Year	Institution	Lecture/Course
2020 - present	Bachelor Program in Nursing, Faculty of Medicine, Sapienza University of Rome (Corso di laurea D/Aeronautica Militare L/SNT1- Sede Policlinico Umberto I°)	Biochemistry – 2 CFU BIO/10
2020- present	Degree in Medicine, Faculty of Pharmacy and Medicine, Sapienza University of Rome (Corso di Laurea D, LM-41)	Biochemistry –1 CFU BIO/10
2020- present	Bachelor Program in Nursing, Faculty of Medicine, Sapienza University of Rome (Corso di laurea J- ASL Roma1 L/SNT1)	Biology – 2 CFU BIO/11
2019- present	Laboratory Safety Course for the students enrolled in the PhD in Biochemistry	Biochemistry – 1 CFU BIO/10
2016 - present	Degree in Medicine, Faculty of Pharmacy and Medicine, Sapienza University of Rome (Corso di Laurea D, LM-41)	Biochemistry (ADE)
2017 - present	International Medical School of Sapienza University of Rome (Corso di Laurea A, LM-41)	Biochemistry (ADE)
2015 - 2019	Degree in Medicine, Faculty of Pharmacy and Medicine, Sapienza University of Rome (Corso di Laurea A, LM-41)	Laboratory practice in Biochemistry
2014-2015	(a) Department of Molecular and Biomedical Pharmacology and (b) Department of Chemistry, Laboratory of Neurochemistry University of Kentucky, Lexington, (KY), USA	Supervisor for master students enrolled at the School of Chemistry

Part V - Society memberships, Awards and Honors

V.A – Society Memberships

Year	Title
2021- present	Member of Italian Society of Neuroscience (SINS)

2018 - present	Member of the International Society for Neurochemistry (ISN)
2018 - present	Member of the European Society for Neurochemistry (ESN)
2018 - present	Member of T21 Research Society (T21RS)
2014 - present	Member of Society for Redox Biology and Medicine (SFRBM)
2013 - present	Member of the Italian Society of Biochemistry and Molecular Biology (SIB)
2010 - present	Member of Society of Neuroscience (SN)

V.B – Executive roles in National/International Scientific Societies

Year	Title
2020-2021	Appointed as Young Member for the International Preclinical Research Committee of Trisomy 21 Research Society (T21RS)
2014-2017	Member of the “Gruppo di lavoro Invecchiamento e Patologie Neurodegenerative” hosted by the Italian Society of Biochemistry and Molecular Biology (SIB)
2013-2017	Member of the “Gruppo di lavoro Malattie Neurodegenerative” hosted by the Italian Society of Pharmacology (SIF)

V.C – Awards

Year	Title
06/2021	ESN Travel Award European society of Neuroscience Conference, Kyoto 2022, Japan
06/2019	ItPA and HPS International Travel Award Italian Proteomic Association Conference, Catanzaro 2019, Italy
06/2018	SFRR-I Travel Award Society for Free Radical Research International (SFRR-I), Lisbon 2018, Portugal
09/ 2017	“Medaglia SIB” Award Young investigator Award from SIB (Italian Society of Biochemistry)
09/2014	SIB Fellowship Award Italian Society of Biochemistry

V.D – National and International Fellowships received as recipient or awarded on a competitive basis

Year	Title
2019	Recipient of a Research fellowship funded by “Fondazione Umberto Veronesi” (awarded on a competitive basis) Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome, Rome, IT
2018	Recipient of a Research fellowship funded by “Fondazione Umberto Veronesi” (awarded on a competitive basis) Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome, Rome, IT
03/2014-01/2015	Selected as recipient Research fellowship funded by the Italian Society of Biochemistry for research training abroad (awarded on a competitive basis) Department of Chemistry – University of Kentucky, Lexington (KY), USA
09/2006-10/2007	Recipient of fellowship funded by “Sapienza University of Rome” (awarded on a competitive basis) Department of Neurological Science, Sapienza University of Rome, Rome, IT
08/2006-02/2007	Selected as recipient of Fellowship funded by University of Perugia for the ERASMUS Project (awarded on a competitive basis) University of Helsinki, Helsinki, Finland

V.E – Editorial Activities

Year	Title
2020	Appointed as Associate Editor for Antioxidants (ISSN 2076-3921)
2019	Appointed as Associate Editor for Frontiers in Neuroscience (ISSN 1662-453X)
2019-2020	Invited Guest Editor for Oxidative Medicine and Cellular Longevity (ISSN: 1942-0994) <i>Special Issue: Proteostasis and Oxidative Stress in Protein Misfolding Diseases</i>
2019	Appointed as Associate Editor of Oxidative Medicine and Cellular Longevity (ISSN: 1942-0994)
2013-present	<i>Ad hoc reviewer</i> per Archives of Biochemistry and Biophysics, Lipids, Experimental Gerontology, Biochemical Pharmacology, Neurochemical Research, BBA General Subjects, Proteomics Clinical Application, Neural Regeneration Research, Advances in Alzheimer’s Disease, Advances in Aging Research, BRAIN, FRBM, Neurobiology of Disease, Cellular Physiology and Biochemistry, Journal of Alzheimer’s Disease, Diabetes, Neuroscience, Scientific Reports, Archives of Biochemistry, BBA Molecular Basis of disease, Scientific Reports, FASEB Journal, PNAS, Antioxidants, International Journal of Molecular Sciences

V.F – Member of scientific/organizing committee for the following national and international seminars/conferences

Year	Title
2021	Organizer and Chair of the selected Symposium entitled “ <i>Current perspectives on the role of oxidative stress in Alzheimer's disease: challenges and therapeutic opportunities</i> ”. 19th SINS National Congress, 9-12 September 2021 (Virtual)

V.G – Honors

Year	Title
2019	Nominated official consultant for Bio-Rad® Laboratories

V.H – Invited Speaker

Year	Title
2021	1. 61°Congresso SIB 2021 “Role of mi-R802 in Down Syndrome” 23-24 Settembre, 2021 (Virtual)
2020	2. Sindrome di Down dalla diagnosi alla terapia IV meeting virtual edition “Ruolo del miR-802 nella Sindrome di Down” 16- 17 October, 2020 (Virtual)
2019	3. ItPA and HPS International XIV Congress: Intranasal Rapamycin in Ts65dn Down Syndrome Mice Reversed Brain mTOR Activation, Prevented AD-like Neuropathology, Improved Cognition, and Reduced Oxidative Damage. 25-27 June 2019, Catanzaro, IT.
2019	4. RIDAIT SEMINARS “ <i>Deciphering the complexity of neurodegeneration: lesson from Down Syndrome</i> ” Istituto Nazionale dei tumori Regina Elena (IFO). 3 December 2019, Rome,IT.

- 2019 5. **40° National Meeting of Endocrinology Society: Danno d'organo nel diabete: Disfunzione cognitiva.** 29 May - 1 June, 2019, Rome, IT.
- 2017 6. **AD/PD Meeting 2017: Polyubiquitome profile in Alzheimer human brain.** April 2017, Wien, AU.
- 2017 7. **Aging Brain Meeting: Altered protein O-GlcNAcylation profile revealed by proteomics in AD: Novel insights on protein signalling mechanisms and potential therapeutic targets.** May 2017, Cosenza, IT
- 2016 8. **Alzheimer Disease, Euroscicon Event: Profile in Down Syndrome Brain Prior to and after the Development of Alzheimer Neuropathology.** June 2016, London, UK

V. I – Invited Poster Presenter as First Author

- 2021 61° Meeting of the Italian Society of Biochemistry and Molecular Biology (SIB) **(September 2021, Virtual Meeting)**
- 2018 The 2nd Meeting for the Italian Society of Pharmacology “More Than Neurons” (SIF). **(December 2018, Torino, Italy)**
- 2018 The 19th biennial Meeting for the Society for Free Radical Research International (SFRRRI). **(June 2018, Lisbon, Portugal)**
- 2017 The 59th Meeting of the Italian Society of Biochemistry and Molecular Biology (SIB). **(September 2017, Caserta, Italy)**
- 2017 The 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, AD/PDTM **(April 2017, Wien, AU)**
- 2016 The 23rd Annual Meeting of the Society for Free Radical Biology (SFRBM). **(November 2016, San Francisco, CA, USA)**
- 2015 The 12th INTERNATIONAL CONFERENCE ON ALZHEIMER'S & PARKINSON'S DISEASES: AD/PDTM **(March 2015. Nice, France)**
- 2014 The 21st Society for Free Radical Biology and Medicine's Annual Meeting **(November 2014, Seattle WA, USA)**
- 2013 The 56th Italian congress of SIB “Società italiana di Biochimica” **(September 2013, Ferrara, Italy)**
- 2011 The 8th International Brain Research Organization (IBRO) World Congress of Neuroscience **(July 2011, Florence, Italy)**

2010 The 40th Society for Neuroscience (SFN) Annual Meeting (November 2010, San Diego, USA)

V. L – Patents

Year	Title
2021	A new application ID #102021000012173 has been submitted and is pending for approval. Ownership: Sapienza University (50%): Inventor: Tramutola Antonella (Sapienza University)

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

VI.A – grants as PI-principal investigator

Year	Title	Program	Grant value
2021	Brain insulin resistance and mitochondrial defects in Alzheimer disease	I , Alzheimer’s Association, Rapid Program in Dementia (RAPID) Funding, Project ID 830355 (the most important international institution funding studies on Alzheimer disease; ONLY this project awarded in Italy)	50.000,00 dollars
2020	Intravital two-photon microscopy coupled with electrophysiology setup: a unique tool to longitudinally study cell morphology and function in awake animal models.	I , Grant from Sapienza University of Rome “Grandi Attrezzature”, Project ID GA12017304B57367	546.077,00 Euro
2020	Aberrant insulin signaling contributes to development of Alzheimer disease in Down syndrome: search for novel therapeutic strategies	I , Jerome Lejeune Foundation, Project ID Cycle 2019b –#1887 (France’s number one funder for research in genetic intelligence disorders, develops and funds programs in France and abroad)	87.000,00 Euro

2020	Unravelling a novel mechanism favoring brain insulin resistance development	I, Alzheimer's Association, Project ID 2019-AARG-643091 (the most important international institution funding studies on Alzheimer disease; ONLY two projects awarded in Italy)	150.000,00 Dollars
2019	Aberrant insulin signaling contributes to development of Alzheimer disease in Down Syndrome: identifying novel drug candidates	PI, "Fondazione Umberto Veronesi", 1-year Post-Doctoral Fellowship ID Project 2029	27.000,00 Euro
2018	Aberrant insulin signaling contributes to development of Alzheimer disease in Down Syndrome: identifying novel drug candidates	PI, "Fondazione Umberto Veronesi", 1-year Post-Doctoral Fellowship ID Project 2197	27.000,00 Euro
2017	Nuove strategie terapeutiche per la prevenzione della malattia di Alzheimer	I, Grant from Banca d'Italia, n. 12868/17 del 5.1.2017	50.000,00 Euro
2017	A Redox Proteomic analysis on T lymphocytes in AD: looking for new biomarkers.	PI, Grant from Sapienza University of Rome "Progetti di Avvio alla Ricerca", Project ID AR21715C81C552B4	2.250,00 Euro
2016	Link between on polyubiquitination and oxidative damage in Down Syndrome	PI, Grant from Sapienza University of Rome "Progetti di Avvio alla Ricerca", Project ID AR216154C8A7B6A9	2.100,00 Euro
2016	Intranasal Rapamycin administration to prevent Alzheimer like dementia in Down Syndrome model	I, Jerome Lejeune Foundation, Project ID #1484 (France's number one funder for research in genetic intelligence disorders, develops and funds programs in France and abroad)	26.000,00 Euro
2015	Crosstalk between insulin signaling and oxidative stress in Alzheimer disease: A new paradigm	I, SIR Program (Scientific Independence of young Researchers) funded by the Italian Ministry of Education, Universities and Research (MIUR), Project ID RBSI144MTL	170.000,00 Euro

VI.C – external agreements

Year	Program	Grant value
2019 - present	Bio-Rad Laboratories, study agreement to develop a protocol for testing new technology of fluorescence antibodies in cell and animal models.	Furniture of material to perform the project

Part VII – Research Activities

Keywords	Brief Description
Alzheimer disease Down Syndrome Type 2 Diabetes Metabolic disorders Oxidative stress Cell Metabolism Insulin signalling mi-RNAs Neurodegeneration Autophagy	My research group is interested in understanding how disturbance of components of the proteostasis network, that provides a critical protective role against stress conditions, may trigger neuronal death. Our works suggest that dysfunction of specific members of the protein quality control, regulating protein folding, surveillance and degradation is caused by oxidative damage. We aim to identify the specific pathways involved in the proteostasis network, which contribute to the development of Alzheimer Disease (AD) by analyzing human post-mortem brain, cell culture and animal models of the disease. Considering that Down syndrome (DS) and AD are characterized by common pathological hallmarks, these studies identify common and divergent mechanisms of neurodegeneration by particularly focusing on mTOR signaling, insulin cascade and the crosstalk between autophagy and proteasome system. Further, this research also could help to investigate how these pathways may represent an ideal therapeutic target to prevent neurodegenerative phenomena.

Research Interests:

1. Aberrant insulin signaling contributes to development of Alzheimer disease in Down Syndrome: identifying novel drug candidates
2. Rescue mTOR signaling in Down Syndrome mice by a novel rapamycin intranasal administration protocol (InRapa) that maximizes brain delivery and reduce systemic side effects.
3. Role of oxidative stress and protein oxidation in Alzheimer disease, Parkinson disease and Down syndrome.

4. Proteomic studies: poly-ubiquitin profile in Alzheimer disease and Down Syndrome
5. Role of mi-RNAs in Down Syndrome

VII.B - Direction or participation to a research group characterized by national or international collaborations

since 2009: Principal Investigator - I established a collaboration with Prof Paola Casolini e Dr. Annarita Zuena (Dept. of Pharmacology at Sapienza, University of Rome, IT). -The principal project was a chapter of my PhD Thesis entitled: *In vivo and in vitro studies on stress, stress related disorders and neuroinflammation*- 2 papers published in rage of this collaboration (<https://pubmed.ncbi.nlm.nih.gov/?term=tramutola+and+zuena&sort=date>). The collaboration is still ongoing.

since 2013: Collaboration with the research group headed by Prof. Silvana Gaetani (Dept. of Pharmacology at Sapienza, University of Rome, IT). - Project: The role of metabolic disorders in Alzheimer Disease- 3 papers published in rage of this collaboration (<https://pubmed.ncbi.nlm.nih.gov/?term=tramutola+and+gaetani&sort=date>). The collaboration is ongoing.

since 2014: Collaboration with the research group headed by Prof. D. Allan Butterfield (University of Kentucky, USA, <https://chem.as.uky.edu/users/dabcns>) - Project: Role of oxidative stress-induced proteins post-translational modifications in ageing and neurodegeneration. - 25 papers published in rage of this collaboration (<https://pubmed.ncbi.nlm.nih.gov/?term=tramutol+a+AND+butterfield+da&sort=date>). The collaboration is ongoing.

since 2015: Collaboration with the research group headed by Prof. Joe Abisambra (University of Florida, USA, <https://neuroscience.ufl.edu/faculty-and-staff-directory/faculty/jose-f-abisambra-ph-d/>). Project: Role of ER stress in Down Syndrome. 2 paper published (link here: <https://www.ncbi.nlm.nih.gov/pubmed/?term=barone+e+AND+abisambra+jf>). The collaboration is ongoing

since 2016: Collaboration with the research group headed by Prof. Uberti Daniela (University of Brescia, Italy). Project: Identification of novel biomarkers in Alzheimer disease: Protein nitration profile of CD3 + lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. 1 paper published (link here: [10.1016/j.freeradbiomed.2018.10.414](https://doi.org/10.1016/j.freeradbiomed.2018.10.414)). The collaboration is ongoing

since 2016: Collaboration with the research group headed by Prof. Tommaso Cassano (University of Foggia, Italy) - Project: Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease- 5 papers published in rage of this collaboration

(<https://pubmed.ncbi.nlm.nih.gov/?term=tramutola+a+AND+cassano+T&sort=date>). The collaboration is ongoing.

since 2018: Principal Investigator - I established a collaboration with the research group headed by Dr. Stefania Petrini (Head of the Confocal Laser Microscopy Core Facility, Research Center, Bambino Gesù Children's Hospital IRCCS, Rome, <https://it.linkedin.com/in/stefania-petrini-8876a332>)- Project: Aberrant insulin signaling contributes to development of Alzheimer disease in Down Syndrome: identifying novel drug candidates. The collaboration and the project are still ongoing.

since 2019: Principal Investigator - I established a new collaboration with the research groups headed by Prof. Squiteri Ferdinando (Scientific IRCCS Network, Head of the "Huntington and Rare Diseases Unit" Mendel Institute Rome). Project: Role of glucose metabolism in Huntington Disease. The collaboration and the project are still ongoing.

Part VIII – Summary of Scientific Achievements

Product type	Number	Year (Start-End)	Database
Articles in peer-reviewed and indexed international Journals (all the journals have an IF)			
Total articles	47	2011-2021	Scopus/WoS
*calculated as indicated in art. 1 of the current call			
Hirsch (H) index	21	2011-2021	Scopus
Normalized H index*	1,75	2009-2021	Scopus
*H index divided by the academic seniority (years from Master degree)			
Total IF	248,59	2011-2021	Journal of Citation Reports (JCR)
Mean IF per article	5,40	2008-2021	

Total Citations	1453	2011-2021	Scopus
Average Citations per Product	31,58	2011-2021	Scopus
First author	16	2011-2021	Scopus/WoS
Second author	14	2011-2021	Scopus/WoS
Last author (not corresponding)	2	2011-2021	Scopus/WoS
% first/second/last/. (46 articles)	69,5%	2011-2021	
Chapter in Scientific and Indexed Books	1	2011-2021	Scopus

Part IX– Selected Publications (15 out of 46)

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

- IF (publication year) is from *Incites-JCR Journal Citation Reports* database. For papers published in 2020 and 2021 the last available IF is indicated
 - Citations number is from *Scopus* database;
 - All scientific publications are from *Medline (PubMed.gov)* & *Scopus* database
1. Perluigi M, Picca A, Montanari E, Calvani R, Marini F, Matassa R, **Tramutola A**, Villani A, Familiari G, Di Domenico F, Butterfield DA, Oh KJ, Marzetti E, Diletta V and Barone E. Aberrant Crosstalk between Insulin signaling and mTOR in young Down Syndrome Individuals Revealed by Neuronal-derived Extracellular Vesicles Alzheimer's and Dementia. Sept. 15 Accepted, Ref N° ADJ-D-21-00447R2
Citations: 0 IF (2019): 21,56
 2. Lanzillotta C, **Tramutola A**, Di Giacomo G, Marini F, Butterfield DA, Di Domenico F, Perluigi M, Barone E. Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: a harmful synergistic path in Down syndrome. *Free Rad Biol Med* (2021), Mar 165:152-170. doi: 10.1016/j.freeradbiomed.2021.01.042.
Citations: 10 IF (2020): 7.37
 3. Romano A, Micioni Di Bonaventura MV, Gallelli CA, Koczwara JB, Smeets D, Giusepponi ME, De Ceglia M, Friuli M, Micioni Di Bonaventura E, Scuderi C, Vitalone A, **Tramutola A**, Altieri F, Lutz TA, Giudetti AM, Cassano, T, Cifani C, Gaetani S. Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder (2020) *Neuropsychopharmacology*, Oct;45(11):1931-1941. doi: 10.1038/s41386-020-0686-z.
Citations: 15 IF (2020): 7.85
 4. **Tramutola A**, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E. Brain insulin resistance triggers early onset Alzheimer disease in Down Syndrome. *Neurobiol Dis* (2020) Apr;137:104772. doi: 10.1016/j.nbd.2020.104772.
Citations: 22 IF (2020): 5.99
 5. **Tramutola A**, Protto V, Fabiani M, Marcocci ME, Napoletani G, Iavarone F, Vincenzoni F, Castagnola M, Perluigi M, Di Domenico F, De Chiara G, Palamara AT. Multiple herpes simplex virus-1 (Hsv-1) reactivations induce protein oxidative damage in mouse brain: Novel mechanisms for alzheimer's disease progression (2020) *Microorganisms*, Jun 29;8(7):972. doi: 10.3390/microorganisms8070972.
Citations: 6 IF (2019): 4.16

6. **Tramutola A**, Falcucci S, Brocco U, Triani F, Lanzillotta C, Donati M, Panetta C, Luzi F, Iavarone F, Vincenzoni F, Castagnola M, Perluigi M, Di Domenico F, De Marco F. Protein oxidative damage in UV-related skin cancer and dysplastic lesions contributes to neoplastic promotion and progression (2020) *Cancers*, Jan 1;12(1):110. doi: 10.3390/cancers12010110.
Citations: 3 IF (2019): 6.16

7. **Tramutola A**, Abate G, Lanzillotta C, Triani F, Barone E, Iavarone F, Vincenzoni F, Castagnola M, Marziano M, Memo M, Garrafa E, Butterfield DA, Perluigi M, Di Domenico F, Uberti D. Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. *Free Rad Biol Med* (2018) Dec;129:430-439. doi: 10.1016/j.freeradbiomed.2018.10.414.
Citations: 14 IF (2018): 5.66

8. Di Domenico F, **Tramutola A**, Barone E, Lanzillotta C, Defever O, Arena A, Zuliani I, Foppoli C, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA and Perluigi M. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: focus on HNE-modified proteins in a mouse model of Down Syndrome. *Redox Biol* (2019) May; 23:101162. doi: 10.1016/j.redox.2019.101162.
Citations: 23 IF (2019): 9.99

9. **Tramutola A**, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L, Blarzino C, Butterfield DA, Perluigi M, Di Domenico F. Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. *Transl Neurodegener* (2018) Nov 6;7:28. doi: 10.1186/s40035-018-0133-9.
Citations: 46 IF (2018): 5.53

10. **Tramutola A**, Triani F, Di Domenico F, Barone E, Cai J, Klein JB, Perluigi M, Butterfield DA. Poly-ubiquitin profile in Alzheimer disease brain. *Neurobiol Dis* (2018) Oct;118:129-141. doi: 10.1016/j.nbd.2018.07.006.
Citations: 18 IF (2018): 5.16

11. **Tramutola A**, Sharma N, Barone E, Lanzillotta C, Castellani A, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Cassano T, Perluigi M, Di Domenico F. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. *BBA-Molecular Basis of Diseases* (2018) Oct;1864(10):3309-3321. doi: 10.1016/j.bbadis.2018.07.017.
Citations: 19 IF (2018): 4.33

12. **Tramutola A**, Di Domenico F, Barone E, Giorgi A, Di Francesco L, Schinà E, Coccia R, Arena A, Head E, Butterfield DA, Perluigi M. Poly-Ubiquitylation Profile in Down Syndrome Brain before and after the Development of Alzheimer Neuropathology. *Antioxid Redox Signal* (2017) Mar 1;26(7):280-298. doi: 10.1089/ars.2016.6686.
Citations: 24 IF (2017): 6.53

13. **Tramutola A**, Pupo G, Di Domenico F, Barone E, Arena A, Lanzillotta C, Broekaart D, Blarmino C, Head E, Butterfield DA and Perluigi M. Activation of p53 in down syndrome and in the ts65dn mouse brain is associated with a pro-apoptotic phenotype. *J Alzheimer Dis* (2016) 52: 359-371. doi: 10.3233/JAD-151105.
Citations: 25 IF (2016): 3.73
14. **Tramutola A**, Lanzillotta C, Arena A, Barone E, Perluigi M and Di Domenico F. Increased mammalian target of rapamycin signaling contributes to the accumulation of protein oxidative damage in a mouse model of Down syndrome. *Neurodegenerative Dis* (2016) 16: 62-68. doi: 10.1159/000441419.
Citations: 30 IF (2016): 2.84
15. **Tramutola A**, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, Perluigi M, Butterfield DA. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with pre-clinical AD, amnesic mild cognitive impairment and late-stage AD (2015) *Journal of Neurochemistry*, Jun;133(5):739-49. doi:10.1111/jnc.13037.
Citations: 173 IF (2015): 3.85

Total articles selected for the evaluation: **15**

First author: in **11** of them

Second author: in **2** of them.

Another author position: in **2** of them.

Total IF: **100,71**

(*Incites JCR Journal Citation Reports database*)

Mean IF per article: **6,71**

Total Citations: **424**

(*Scopus database*)

Mean citations per article: **27**

PART X: LIST OF ALL SCIENTIFIC PUBLICATIONS (2011-2021) in peer-reviewed journals used to calculate the bibliometric indexes.

- IF (publication year) is from *Incites-JCR Journal Citation Reports* database. For papers published in 2020 and 2021 the last available IF is indicated
- Citations number is from *Scopus* database
- All scientific publications are from *Medline (PubMed.gov)* & *Scopus* database

1. Perluigi M, Picca A, Montanari E, Calvani R, Marini F, Matassa R, **Tramutola A**, Villani A, Familiari G, Di Domenico F, Butterfield DA, Oh KJ, Marzetti E, Diletta V and Barone E. Aberrant Crosstalk between Insulin signaling and mTOR in young Down Syndrome Individuals Revealed by Neuronal-derived Extracellular Vesicles Alzheimer's and Dementia. Sept. 15 Accepted, Ref N° ADJ-D-21-00447R2
Citations: 0 IF (2020): 21,56
2. Barchetta I, Ceccarelli V, Cimini FA, Barone E, Sentinelli F, Coluzzi M, Chiappetta C, Bertocchini L, **Tramutola A**, Labbadia G, Di Cristofano C, Silecchia G, Leonetti F, Cavallo MG. Circulating dipeptidyl peptidase- 4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. *J Endocrinol Invest* (2021), May;44(5):979-988. doi: 10.1007/s40618-020-01392-5
Citations: 3 IF (2019): 3.40
3. Zuliani I, Lanzillotta C, **Tramutola A**, Barone E, Perluigi M, Rinaldo S, Paone A, Cutruzzola F, Bellanti F, Spinelli M, Natale F, Fusco S, Grassi C, Di Domenico F. High fat diet leads to reduced protein O-GlcNAcylation and mitochondrial defects promoting the development of Alzheimer's Disease signatures. *I J Mol Sci* (2021), Apr 3;22(7):3746. doi: 10.3390/ijms22073746.
Citations: 2 IF (2020): 5.92
4. Lanzillotta C, **Tramutola A**, Di Giacomo G, Marini F, Butterfield DA, Di Domenico F, Perluigi M, Barone E. Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: a harmful synergistic path in Down syndrome. *Free Rad Biol Med* (2021), Mar 165:152-170. doi: 10.1016/j.freeradbiomed.2021.01.042.
Citations: 10 IF (2020): 7.37

5. Zuliani I, Lanzillotta C, **Tramutola A**, Francioso A, Pagnotta S, Barone E, Perluigi M, Di Domenico F. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome. *Neurotherapeutics* (2021), Jan;18(1):340-363. doi: 10.1007/s13311-020-00978-4.
Citations: 2 IF (2020): 7.62

6. Perluigi M, **Tramutola A**, Pagnotta S, Barone E and Butterfield DA. The BACH1/Nrf2 Axis in Brain in Down Syndrome and Transition to Alzheimer Disease-Like Neuropathology and Dementia. *Antioxidants* (2020) Aug 21;9(9):779. doi: 10.3390/antiox9090779..
Citations: 3 IF (2020): 5.29

7. Lanzillotta C, Zuliani I, **Tramutola A**, Barone E, Blarzino C, Folgiero V, Caforio M, Valentini D, Villani A, Locatelli F, Butterfield DA, Head E, Perluigi M, Abisambra JF and Di Domenico F. Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: insights for therapeutic intervention. *Progress in Neurobiol* (2020), Jan;196:101892. doi: 10.1016/j.pneurobio.2020.101892.
Citations: 8 IF (2020): 11.68

8. Bouzidi A, Magnifico MC, Paiardini A, Macone A, Boumis G, Giardina G, Rinaldo S, Liberati, F.R., Lauro C, Limatola C, Lanzillotta C, **Tramutola A**, Perluigi M, Sgarbi G, Solaini G, Baracca A, Paone A, Cutruzzolà F. Cytosolic serine hydroxymethyltransferase controls lung adenocarcinoma cells migratory ability by modulating AMP kinase activity (2020) *Cell Death Dis.* 2020 Nov 26;11(11):1012. doi: 10.1038/s41419-020-03215-0.
Citations: 1 IF (2020): 6.30

9. Romano A, Micioni Di Bonaventura MV, Gallelli CA, Koczwara JB, Smeets D, Giusepponi ME, De Ceglia M, Friuli M, Micioni Di Bonaventura E, Scuderi C, Vitalone A, **Tramutola A**, Altieri F, Lutz TA, Giudetti AM, Cassano, T, Cifani C, Gaetani S. Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder (2020) *Neuropsychopharmacology*, Oct;45(11):1931-1941. doi: 10.1038/s41386-020-0686-z.
Citations: 15 IF (2020): 7.85

10. **Tramutola A**, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E. Brain insulin resistance triggers early onset Alzheimer disease in Down Syndrome. *Neurobiol Dis* (2020) Apr;137:104772. doi: 10.1016/j.nbd.2020.104772.
Citations: 22 IF (2020): 5.99

11. Höhn A, **Tramutola A**, Cascella R. Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress (2020) *Oxidative Medicine and Cellular Longevity*, (2020). Mar 27;2020:5497046. doi: 10.1155/2020/5497046.
Citations: 18 IF (2020): 5.07

12. Protto V, **Tramutola A*** (co-first authors), Fabiani M, Marcocci ME, Napoletani G, Iavarone F, Vincenzoni F, Castagnola M, Perluigi M, Di Domenico F, De Chiara G, Palamara AT. Multiple herpes simplex virus-1 (Hsv-1) reactivations induce protein oxidative damage in mouse brain: Novel

mechanisms for alzheimer's disease progression (2020) *Microorganisms*, Jun 29;8(7):972. doi: 10.3390/microorganisms8070972.

Citations: 6 IF (2019): 4.16

13. **Tramutola A**, Falcucci S, Brocco U, Triani F, Lanzillotta C, Donati M, Panetta C, Luzi F, Iavarone F, Vincenzoni F, Castagnola M, Perluigi M, Di Domenico F, De Marco F. Protein oxidative damage in UV-related skin cancer and dysplastic lesions contributes to neoplastic promotion and progression (2020) *Cancers*, Jan 1;12(1):110. doi: 10.3390/cancers12010110.
Citations: 3 IF (2019): 6.16
14. Di Domenico F, Zuliani I, **Tramutola A**. Shining a light on defective autophagy by proteomics approaches: implications for neurodegenerative illnesses (2019) *Expert Review of Proteomics*, 16 (11-12), pp. 951-964.
Citations: 4 IF (2019): 3.614
15. Barchetta I, Ciccarelli G, Barone E, Cimini FA, Ceccarelli V, Bertocchini L, Sentinelli F, **Tramutola A**, Del Ben M, Angelico F, Baroni MG, Lenzi A, Cavallo MG. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. *Nutrition, Metabolism and Cardiovascular Diseases* (2019) Oct;29(10): 1087-1094. doi: 10.1016/j.numecd.2019.07.010.
Citations: 6 IF (2019): 3.70
16. Di Domenico F, **Tramutola A**, Barone E, Lanzillotta C, Defever O, Arena A, Zuliani I, Foppoli C, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA and Perluigi M. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: focus on HNE-modified proteins in a mouse model of Down Syndrome. *Redox Biol* (2019) May; 23:101162. doi: 10.1016/j.redox.2019.101162.
Citations: 23 IF (2019): 9.99
17. Cimini FA, Arena A, Barchetta I, **Tramutola A**, Ceccarelli V, Lanzillotta C, Fontana M, Bertocchini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano G, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E. Reduced biliverdin reductase-A are associated with early alterations of insulin signalling in obesity. *BBA Mol Bas Dis* (2019) Jun 1;1865(6):1490-1501. doi: 10.1016/j.bbadis.2019.02.021.
Citations: 18 IF (2019): 4.35
18. Sharma N, **Tramutola A**, Lanzillotta C, Arena A, Blarzino C, Cassano T, Butterfield DA, Di Domenico F, Perluigi M, Barone E. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. *Neurobiol Dis* (2019) May;125:176-189. doi: 10.1016/j.nbd.2019.02.003.
Citations: 29 IF (2019): 5.33
19. **Tramutola A**, Abate G, Lanzillotta C, Triani F, Barone E, Iavarone F, Vincenzoni F, Castagnola M, Marziano M, Memo M, Garrafa E, Butterfield DA, Perluigi M, Di Domenico F, Uberti D. Protein nitration profile of CD3⁺ lymphocytes from Alzheimer disease patients: Novel hints on

- immunosenescence and biomarker detection. *Free Rad Biol Med* (2018) Dec;129:430-439. doi: 10.1016/j.freeradbiomed.2018.10.414.
Citations: 14 IF (2018): 5.66
20. **Tramutola A**, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L, Blarmino C, Butterfield DA, Perluigi M, Di Domenico F. Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. *Transl Neurodegener* (2018) Nov 6;7:28. doi: 10.1186/s40035-018-0133-9.
Citations: 46 IF (2018): 5.53
21. **Tramutola A**, Triani F, Di Domenico F, Barone E, Cai J, Klein JB, Perluigi M, Butterfield DA. Polyubiquitin profile in Alzheimer disease brain. *Neurobiol Dis* (2018) Oct;118:129-141. doi: 10.1016/j.nbd.2018.07.006.
Citations: 18 IF (2018): 5.16
22. Triani F, **Tramutola A**, Di Domenico F, Sharma N, Butterfield DA, Head E, Perluigi M, Barone E. Biliverdin reductase-A impairment links brain insulin resistance with increased A β production in an animal model of aging: Implications for Alzheimer disease. *BBA-Molecular Basis of Diseases* (2018) Oct;1864(10):3181-3194. doi: 10.1016/j.bbadis.2018.07.005.
Selected to be included in the BBA Collection on Cellular Aging and Senescence in 2019
Citations: 21 IF (2018): 4.35
23. **Tramutola A**, Sharma N, Barone E, Lanzillotta C, Castellani A, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Cassano T, Perluigi M, Di Domenico F. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. *BBA-Molecular Basis of Diseases* (2018) Oct;1864(10):3309-3321. doi: 10.1016/j.bbadis.2018.07.017.
Citations: 19 IF (2018): 4.33
24. Barone E, **Tramutola A**, Triani F, Calcagnini S, Di Domenico F, Ripoli C, Gaetani S, Grassi C, Butterfield DA, Cassano T and Perluigi M. Biliverdin reductase-A mediates the beneficial effects of intranasal insulin administration in Alzheimer disease. *Molecular Neurobiology* (2019) Apr;56(4):2922-2943. doi: 10.1007/s12035-018-1231-5.
Citations: 43 IF (2019): 4.5
25. Di Domenico, F., Lanzillotta, C., **Tramutola, A.** Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies (2019) *Expert Review of Neurotherapeutics*, Jan;19(1):1-3. doi: 10.1080/14737175.2019.1540932.
Citations: 9 IF (2019): 3.74
26. Lanzillotta C, **Tramutola A**, Meier S, Schmitt F, Barone E, Perluigi M, Di Domenico F, Abisambra JF. Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models. *J Alzheimers Dis* (2018) 62:347-359. doi: 10.3233/JAD-170617.
Citations: 12 IF (2018): 3.52

27. Di Domenico F, **Tramutola A**, Foppoli C, Head E, Perluigi M, Butterfield DA. mTOR in Down syndrome: Role in A β and tau neuropathology and transition to Alzheimer disease-like dementia (2018) *Free Radical Biology and Medicine*, Jan;114:94-101. doi:10.1016/j.freeradbiomed.2017.08.009.
Citations: 53 IF (2018): 5.606
28. Di Domenico F, **Tramutola A**, Butterfield DA. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of Alzheimer disease and other selected age-related neurodegenerative disorders (2017) *Free Radical Biology and Medicine*, Oct;111:253-261. doi: 10.1016/j.freeradbiomed.2016.10.490.
Citations: 111 IF (2017): 5.606
29. **Tramutola A**, Lanzillotta C, Perluigi M, Butterfield DA. Oxidative stress, protein modification and Alzheimer disease (2017) *Brain Research Bulletin*, Jul;133:88-96. doi: 10.1016/j.brainresbull.2016.06.005.
Citations: 139 IF (2017): 4.07
30. **Tramutola A**, Arena A, Cini C, Butterfield DA, Barone E. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. *Expert Rev Neurother* (2017) Jan;17(1):59-75. doi: 10.1080/14737175.2017.1246183.
Citations: 19 IF (2017): 3.70
31. **Tramutola A**, Di Domenico F, Barone E, Giorgi A, Di Francesco L, Schininà E, Coccia R, Arena A, Head E, Butterfield DA, Perluigi M. Poly-Ubiquitinylation Profile in Down Syndrome Brain before and after the Development of Alzheimer Neuropathology. *Antioxid Redox Signal* (2017) Mar 1;26(7):280-298. doi: 10.1089/ars.2016.6686.
Citations: 24 IF (2017): 6.53
32. **Tramutola A**, Lanzillotta C, Di Domenico F. Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies (2017) *Expert Review of Neurotherapeutics*, Jan;17(1):33-45. doi: 10.1080/14737175.2017.1244482.
Citations: 39 IF (2017): 3.70
33. Di Domenico F, **Tramutola A**, Perluigi M. Cathepsin D as a therapeutic target in Alzheimer's disease. (2016) *Expert Opinion on Therapeutic Targets*, Dec;20(12):1393-1395. doi: 10.1080/14728222.2016.1252334.
Citations: 21 Impact factor (2016): 4.872
34. **Tramutola A**, Pupo G, Di Domenico F, Barone E, Arena A, Lanzillotta C, Broekaart D, Blarzino C, Head E, Butterfield DA and Perluigi M. Activation of p53 in down syndrome and in the ts65dn mouse brain is associated with a pro-apoptotic phenotype. *J Alzheimer Dis* (2016) 52: 359-371. doi: 10.3233/JAD-151105.
Citations: 25 IF (2016): 3.73

35. Barone E, Di Domenico F, Cassano T, Arena A, **Tramutola A**, Lavecchia MA, Coccia R, Butterfield DA, Perluigi M. Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. *Free Rad Biol Med* (2016) Feb;91:127-42. doi: 10.1016/j.freeradbiomed.2015.12.012.
Citations: 67 IF (2016): 5.60
36. **Tramutola A**, Di Domenico F, Barone E, Perluigi M, Butterfield DA. It's all about U(biquitin): Role of the altered ubiquitin proteasome system and UCHL1 in Alzheimer disease. *Oxidative Medicine and Cellular Longevity* (2016) 2016: 2756068. doi: 10.1155/2016/2756068.
Citations: 56 IF (2016): 4.59
37. Di Domenico F, Pupo G, Giraldo E, Badia MC, Monllor P, Lloret A, Schininà ME, Giorgi A, Cini C, **Tramutola A**, Butterfield DA, Viña J, Perluigi M. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients (2016) *Free Radical Biology and Medicine*, Feb;91:1-9. doi: 10.1016/j.freeradbiomed.2015.12.004.
Citations: 51 IF (2016): 5.60
38. **Tramutola A**, Lanzillotta C, Arena A, Barone E, Perluigi M and Di Domenico F. Increased mammalian target of rapamycin signaling contributes to the accumulation of protein oxidative damage in a mouse model of Down syndrome. *Neurodegenerative Dis* (2016) 16: 62-68. doi: 10.1159/000441419.
Citations: 30 IF (2016): 2.84
39. Perluigi M, Pupo G, **Tramutola A**, Cini C, Coccia R, Barone E, Head E, Butterfield DA, Di Domenico F. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. *BBA – Molecular basis of Disease* (2014) Jul;1842(7):1144-53. doi: 10.1016/j.bbadis.2014.04.007.
Citations: 99 IF (2014): 4.88
40. Triplett JC, **Tramutola A**, Swomley A, Kirk J, Grimes K, Lewis K, Orr M, Rodriguez K, Cai J, Klein JB, Perluigi M, Buffenstein R, Butterfield DA. Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity (2015) *Biochimica et Biophysica Acta - Molecular Basis of Disease*, Oct, 1852 (10), pp. 2213-2224. doi: 10.1016/j.bbadis.2015.08.002
Citations: 37 IF (2015): 2.81
41. **Tramutola A**, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, Perluigi M, Butterfield DA. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with pre-clinical AD, amnesic mild cognitive impairment and late-stage AD (2015) *Journal of Neurochemistry*, Jun;133(5):739-49. doi:10.1111/jnc.13037.
Citations: 173 IF (2015): 3.85

42. Lisi L, **Tramutola A**, Navarra P, Dello Russo C. Antiretroviral agents increase NO production in gp120/IFN γ -stimulated cultures of rat microglia via an arginase-dependent mechanism (2014) *Journal of Neuroimmunology*, Jan 15;266(1-2):24-32. doi: 10.1016/j.jneuroim.2013.10.013.
Citations: 13 IF (2014): 1.20
43. Di Domenico F, Pupo G, **Tramutola A**, Giorgi A, Schininà ME, Coccia R, Head E, Butterfield DA, Perluigi M. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: Clues for understanding the development of Alzheimer disease (2014) *Free Radical Biology and Medicine*, Jun;71:270-280. doi: 10.1016/j.freeradbiomed.2014.03.027.
Citations: 72 IF (2014): 6.44
44. Zuena AR, Giuli C, Venerosi Pesciolini A, **Tramutola A**, Ajmone-Cat MA, Cinque C, Alemà GS, Giovine A, Peluso G, Minghetti L, Nicolai R, Calamandrei G, Casolini P. Transplacental Exposure to AZT Induces Adverse Neurochemical and Behavioral Effects in a Mouse Model: Protection by L-Acetylcarnitine. *PLoS One*. 2013;8(2):e55753. doi: 10.1371/journal.pone.0055753.
Citations: 9 IF (2013): 3.53
45. Cinque C, Zuena AR, Catalani A, Giuli C, **Tramutola A**, Scaccianoce S. Maternal exposure to low levels of corticosterone during lactation increases social play behavior in rat adolescent offspring (2012) *Rev Neurosci*. 2012;23(5-6):723-30. doi: 10.1515/revneuro-2012-0077.
Citations: 3 IF (2012):2.41
46. Lisi L, **Tramutola A**, De Luca A, Navarra P, Dello Russo C. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 (2012) *Journal of Neurochemistry*, Jan;120(1):106-14. doi: 10.1111/j.1471-4159.2011.07549.x.
Citations: 27 IF (2012) : 3.97
47. De Corato A, Lisi L, Capuano A, Tringali G, **Tramutola A**, Navarra P, Dello Russo C. Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1 β pro-inflammatory effects (2011) *Journal of Neuroimmunology*, Aug 15;237(1-2):39-46. doi: 10.1016/j.jneuroim.2011.05.013.
Citations: 30 IF (2011):1.27

Chapter in Scientific and Indexed Books

Tramutola, A., Perluigi, M. Polyubiquitin Profile in Down Syndrome and Alzheimer's Disease Brain (2021) *Methods in Molecular Biology*, 2261, pp. 79-91.

Roma, 28 settembre 2021

A handwritten signature in dark ink, appearing to read "Subiella / Tola", is written over a dark, rectangular redaction mark.

Firma

(non soggetta ad autentica ai sensi dell'art. 39 del D.P.R. 28.12.2000, n. 445)